Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q4 2019 · 10-K
Revenue$74.20M$74.20M+1.1% vs Q4 2018 Net Income-$2.20M-$2.20MN/M vs Q4 2018 EPS Diluted-$0.07-$0.07N/M vs Q4 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$15,656,000−63.0% Free Cash Flowderived$14,767,000−63.6% Margins · derivedGross margin33.8%
Operating margin-3.2%−18.2 pt vs Q4 2018
Net margin-3.0%−15.3 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 27, 2020 · 58 d after period end